Find Funding Opportunities

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIH Blueprint for Neuroscience Research R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. This FOA solicits Research Education Grant (R25) applications to develop and implement short courses on neurotherapeutics development for academic neuroscientists. The short courses should provide participants with a sufficient overview of the neurotherapeutics development process to (1) understand the steps required for therapeutics development, (2) anticipate and overcome common challenges in the process, and (3) interact effectively with collaborators who have expertise in various aspects of therapeutics development. The short courses should primarily target independent academic neuroscience researchers and senior post-doctoral fellows interested in incorporating treatment development into their research programs.

The purpose of this notice is to inform applicants of a change to the Key Dates for RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)".

The purpose of this notice is to correct the Application Due Date for NOT-NS-21-068 "HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Advance the Study of Chronic Overlapping Pain Conditions (COPCs)". Applications will be accepted through November 5, 2021, by 5:00PM local time of the applicant organization.

The purpose of this notice is to inform applicants of a change to the Application Types Allowed for RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)". The application types have been expanded to include Resubmission applications. This change is effective as of the October 15, 2021 due date.

The purpose of this notice is to inform applicants of a correction to the Letter of Intent (LOI) due date for PAR-22-026 "Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed)". The LOI is due October 8, 2021; this is 30 days prior to the application due date.

Policy notice for BRAIN Initiative PEDP. The BRAIN Initiative will include a new component in most FOAs requiring that applications include a Plan for Enhancing Diverse Perspectives (PEDP) in the proposed research.

The purpose of this notice is to inform interested applicants of a change to the Key Dates for PAR-19-171 "Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)".

This notice informs applicants of an extension to PA-18-937 "Research on Chronic Overlapping Pain Conditions (R01 Clinical Trial Optional)". This Funding Opportunity Announcement (FOA) has been extended by one additional council round. The following New Application due date has been added: February 5, 2022. This FOA will expire May 8, 2022.

This notice informs applications of an extension to PA-18-939 "Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed)". This Funding Opportunity Announcement (FOA) has been extended by one additional council round. The following New Application due date has been added: February 16, 2022. This FOA will expire May 8, 2022.

The purpose of this notice is to provide further clarification of the clinical trials permitted in PAR-20-316 "Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)". This notice is intended to provide more guidance in developing grant applications that are more responsive to the scientific scope of the Funding Opportunity Announcements.